Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice

Journal of Interventional Cardiology

Volumn 25, Issue 5, 2012, Pages 482-492

  Kovacic, Jason C ^a   Lee, Paul ^a   Karajgikar, Rucha ^a   Baber, Usman ^a   Narechania, Birju ^a   Suleman, Javed ^a   Moreno, Pedro R ^a   Sharma, Samin K ^a   Kini, Annapoorna S ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CATARACT EXTRACTION; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DENTAL SURGERY; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG WITHDRAWAL; DUAL ANTIPLATELET THERAPY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SURGERY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGEON; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SMOKING; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

AGED; ANALYSIS OF VARIANCE; ASPIRIN; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK ASSESSMENT; TICLOPIDINE; TIME FACTORS;

EID: 84867100783     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2012.00746.x     Document Type: Article

References (37)

1. Schulz S, Schuster T, Mehilli J, et al,. Stent thrombosis after drug-eluting stent implantation: Incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J 2009; 30: 2714-2721.
2. Wenaweser P, Daemen J, Zwahlen M, et al,. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008; 52: 1134-1140.
3. Stone GW, Moses JW, Ellis SG, et al,. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
4. Mauri L, Hsieh WH, Massaro JM, et al,. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029.
5. Stettler C, Wandel S, Allemann S, et al,. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 2007; 370: 937-948.
6. Daemen J, Wenaweser P, Tsuchida K, et al,. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
7. Machecourt J, Danchin N, Lablanche JM, et al,. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: The EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007; 50: 501-508.
8. Roy P, Bonello L, Torguson R, et al,. Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation. Am J Cardiol 2009; 103: 801-805.
9. Shuldiner AR, O'Connell JR, Bliden KP, et al,. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-857.
10. Finn AV, Joner M, Nakazawa G, et al,. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-2441.
11. Joner M, Finn AV, Farb A, et al,. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
12. Kuchulakanti PK, Chu WW, Torguson R, et al,. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006; 113: 1108-1113.
13. Iakovou I, Schmidt T, Bonizzoni E, et al,. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130.
14. Levine GN, Bates ER, Blankenship JC, et al,. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58: e44-e122.
15. Farb A, Boam AB,. Stent thrombosis redux-the FDA perspective. N Engl J Med 2007; 356: 984-987.
16. Mehta SR, Yusuf S, Peters RJ, et al,. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527-533.
17. Eisenstein EL, Anstrom KJ, Kong DF, et al,. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297: 159-168.
18. Butler MJ, Eccleston D, Clark DJ, et al,. The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. Am Heart J 2009; 157: 899-907.
19. Kimura T, Morimoto T, Nakagawa Y, et al,. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119: 987-995.
20. Airoldi F, Colombo A, Morici N, et al,. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116: 745-754.
21. Park SJ, Park DW, Kim YH, et al,. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362: 1374-1382.
22. Maisel WH,. Unanswered questions-drug-eluting stents and the risk of late thrombosis. N Engl J Med 2007; 356: 981-984.
23. Beohar N, Davidson CJ, Kip KE, et al,. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007; 297: 1992-2000.
24. Win HK, Caldera AE, Maresh K, et al,. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007; 297: 2001-2009.
25. Cutlip DE, Windecker S, Mehran R, et al,. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
26. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. 2006. Available at: http://www.who.int/diabetes/ publications/Definition%20and%20diagnosis%20of%20diabetes-new.pdf. Accessed 20 January 2012.
27. Taffs R,. Checking the proportional hazard assumption with Kaplan-Meier survival estimates. JMPer Cable (SAS/JMP Newsletter). 18-20.
28. Hoye A, Iakovou I, Ge L, et al,. Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: Predictors of an adverse outcome. J Am Coll Cardiol 2006; 47: 1949-1958.
29. Garg S, Sarno G, Garcia-Garcia HM, et al,. A new tool for the risk stratification of patients with complex coronary artery disease: The Clinical SYNTAX Score. Circ Cardiovasc Interv 2010; 3: 317-326.
30. Terpening C,. An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events. J Am Board Fam Med 2009; 22: 51-56.
31. Boggon R, van Staa TP, Timmis A, et al,. Clopidogrel discontinuation after acute coronary syndromes: Frequency, predictors and associations with death and myocardial infarction-A hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J 2011; 32: 2376-2386.
32. Nakazawa G, Otsuka F, Nakano M, et al,. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57: 1314-1322.
33. Tsai TT, Nallamothu BK, Bates ER,. Letter by Tsai et al. regarding article, "correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and Paclitaxel-eluting stents". Circulation 2006; 114: e362; author reply e363.
34. Yusuf S, Zhao F, Mehta SR, et al,. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
35. Eisenberg MJ, Richard PR, Libersan D, et al,. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009; 119: 1634-1642.
36. Ferreira-Gonzalez I, Marsal JR, Ribera A, et al,. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation 2010; 122: 1017-1025.
37. Gage BF, Waterman AD, Shannon W, et al,. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.